ANI Pharmaceuticals reported Q3 2026 net revenues of $290.8 million, an increase of 27.6% year-over-year, alongside its strategic offer to acquire Egetis Therapeutics for market growth in rare diseases.
ANI Pharmaceuticals reported Q3 2026 net revenues of $290.8 million, an increase of 27.6% year-over-year, alongside its strategic offer to acquire Egetis Therapeutics for market growth in rare diseases.